Verona Pharma (VRNA) Stock Forecast, Price & News

Verona Pharma (NASDAQ:VRNA) Frequently Asked Questions

Is Verona Pharma a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Verona Pharma stock.
View analyst ratings for Verona Pharma or view top-rated stocks.

Are investors shorting Verona Pharma?

Verona Pharma saw a decline in short interest in April. As of April 30th, there was short interest totaling 32,300 shares, a decline of 46.5% from the April 15th total of 60,400 shares. Based on an average trading volume of 72,200 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.1% of the company's shares are short sold.
View Verona Pharma's Short Interest.

When is Verona Pharma's next earnings date?

Verona Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Verona Pharma.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) issued its earnings results on Thursday, March, 3rd. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10.
View Verona Pharma's earnings history.

What price target have analysts set for VRNA?

2 analysts have issued 1-year price objectives for Verona Pharma's shares. Their forecasts range from $17.00 to $25.00. On average, they expect Verona Pharma's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 437.1% from the stock's current price.
View analysts' price targets for Verona Pharma or view top-rated stocks among Wall Street analysts.

Who are Verona Pharma's key executives?

Verona Pharma's management team includes the following people:

• Dr. David S. Zaccardelli, Pres, CEO & Exec. Director (Age 57, Pay $627.27k) (LinkedIn Profile)
• Mr. Mark W. Hahn, Chief Financial Officer (Age 59, Pay $639.08k) (LinkedIn Profile)
• Dr. Kathleen A. Rickard, Chief Medical Officer (Age 64, Pay $562.38k)
• Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 55)
• Ms. Victoria Stewart, Director of Communications
• Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 60)
• Dr. Tara Rheault M.P.H., Ph.D., Sr. VP of R&D (Age 45)
• Ms. Nina Church, Exec. Director of Global Clinical Devel.
• Mr. Christopher Martin, Sr. VP of Commercial
• Ms. Caroline Diaz, Sr. VP of Regulatory Affairs

Who are some of Verona Pharma's key competitors?

Some companies that are related to Verona Pharma include Ventyx Biosciences (VTYX), MannKind (MNKD), Acerus Pharmaceuticals (TRLPF), Nuvation Bio (NUVB), SIGA Technologies (SIGA), Procaps Group (PROC), I-Mab (IMAB), Keros Therapeutics (KROS), BELLUS Health (BLU), Enanta Pharmaceuticals (ENTA), Morphic (MORF), Kura Oncology (KURA), ADVANZ PHARMA (CXRXF), Chinook Therapeutics (KDNY) and Syndax Pharmaceuticals (SNDX).
View all of VRNA's competitors.

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an initial public offering on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Management Group LLP (6.26%), Citigroup Inc. (0.61%), GSA Capital Partners LLP (0.02%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Verona Pharma stock include Anders Ullman, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn and Patrick John Finn.
View institutional ownership trends for Verona Pharma.

Which institutional investors are selling Verona Pharma stock?

VRNA stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, and Simplex Trading LLC. Company insiders that have sold Verona Pharma company stock in the last year include David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, and Mark W Hahn.
View insider buying and selling activity for Verona Pharma or view top insider-selling stocks.

Which institutional investors are buying Verona Pharma stock?

VRNA stock was bought by a variety of institutional investors in the last quarter, including Citigroup Inc., and GSA Capital Partners LLP.
View insider buying and selling activity for Verona Pharma or or view top insider-buying stocks.

How do I buy shares of Verona Pharma?

Shares of VRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $3.91.

How much money does Verona Pharma make?

Verona Pharma has a market capitalization of $236.04 million and generates $40 million in revenue each year. The company earns $-55.57 million in net income (profit) each year or ($1.190010) on an earnings per share basis.

How many employees does Verona Pharma have?

Verona Pharma employs 24 workers across the globe.

What is Verona Pharma's official website?

The official website for Verona Pharma is www.veronapharma.com.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company can be reached via phone at 011-44-0-2032834200 or via email at [email protected].